^
BIOMARKER:

BRAF V600K

i
Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Entrez ID:
Related biomarkers:
BRAF V600K
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
BRAF V600K
Melanoma
trametinib
Sensitive: A1 - Approval
BRAF V600K
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
BRAF V600K
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
BRAF V600K
Cutaneous Melanoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
BRAF V600K
Cutaneous Melanoma
pembrolizumab
Sensitive: A2 - Guideline
BRAF V600K
Cutaneous Melanoma
nivolumab
Sensitive: A2 - Guideline
BRAF V600K
Melanoma
dabrafenib
Sensitive: A2 - Guideline
BRAF V600K
Cutaneous Melanoma
binimetinib + encorafenib
Sensitive: A2 - Guideline
BRAF V600K
Melanoma
pembrolizumab
Sensitive: B - Late Trials
BRAF V600K
Melanoma
encorafenib
Sensitive: B - Late Trials
BRAF V600K
Cutaneous Melanoma
trametinib
Sensitive: C1 - Off-label
BRAF V600K
Solid Tumor
binimetinib + encorafenib
Sensitive: C1 - Off-label
BRAF V600K
Melanoma
pembrolizumab + trametinib + dabrafenib
Sensitive: C2 – Inclusion Criteria
BRAF V600K
Melanoma
vemurafenib + atezolizumab + cobimetinib
Sensitive: C2 – Inclusion Criteria
BRAF V600K
Solid Tumor
trametinib + dabrafenib + AT13387
Sensitive: C2 – Inclusion Criteria
BRAF V600K
Melanoma
nivolumab
Sensitive: C2 – Inclusion Criteria
BRAF V600K
Melanoma
vemurafenib
Sensitive: C2 – Inclusion Criteria
BRAF V600K
Melanoma
BGB-283
Sensitive: C3 – Early Trials
BRAF V600K
Melanoma
9-ING-41
Sensitive: C3 – Early Trials
BRAF V600K
Melanoma
PD1 inhibitor + CTLA4 inhibitor
Sensitive: C3 – Early Trials
BRAF V600K
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials